Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 208Carcinoma, Ovarian Epithelial 133Fallopian Tube Neoplasms 117Uterine Cervical Neoplasms 103Breast Neoplasms 76Endometrial Neoplasms 73Pancreatic Neoplasms 33Neoplasms 31Colonic Neoplasms 28Stomach Neoplasms 27Carcinoma, Non-Small-Cell Lung 27Prostatic Neoplasms 26Testicular Neoplasms 24Sarcoma 23Lung Neoplasms 23Melanoma 22Carcinoma, Renal Cell 22Rectal Neoplasms 21Colorectal Neoplasms 20Vaginal Neoplasms 18Uterine Cervical Dysplasia 18Carcinoma, Hepatocellular 18Neoplasm Metastasis 17Anus Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Esophageal Neoplasms 16Brenner Tumor 16Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Vulvar Neoplasms 14

Interventions

Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Granulosa cell tumor of the ovary × Gynecologic × Clear all
NCT00748657 2019-07-23

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 7 charts
Gynecologic

Granulosa cell tumor of the ovary, Ovarian gynandroblastoma, Sertoli-Leydig Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡